Adamas Pharma (ADMS) Announces FDA Approval for Second Indication for GOCOVRI as Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes

Go back to Adamas Pharma (ADMS) Announces FDA Approval for Second Indication for GOCOVRI as Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes
ADAMAS PHARMACEUT (NASDAQ: ADMS) Delayed: 5.60 +0.18 (3.32%)
Previous Close $5.42    52 Week High $31.84 
Open $5.40    52 Week Low $12.02 
Day High $5.71    P/E N/A 
Day Low $5.38    EPS $0.00 
Volume 183,688